Bio-Techne Corporation (TECH) |
| 71.36 0.06 (0.08%) 07-13 16:00 |
| Open: | 71.1 |
| High: | 71.49 |
| Low: | 71.1 |
| Volume: | 2,176,582 |
| Market Cap: | 11,173(M) |
| PE Ratio: | 36.78 |
| Exchange: | NASDAQ |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 83.50 |
| Resistance 1: | 71.49 |
| Pivot price: | 68.14 |
| Support 1: | 58.99 |
| Support 2: | 51.27 |
| 52w High: | 72.16 |
| 52w Low: | 43.2 |
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
| EPS | 0.700 |
| Book Value | 13.320 |
| PEG Ratio | 0.95 |
| Gross Profit | 5.160 |
| Profit Margin (%) | 9.05 |
| Operating Margin (%) | 25.19 |
| Return on Assets (ttm) | 7.4 |
| Return on Equity (ttm) | 5.3 |
Wed, 08 Jul 2026
Bio-Techne (TECH) Launches AI Proteins As Valuation Questions Come Back Into Focus - simplywall.st
Wed, 08 Jul 2026
Bio-Techne expands designer proteins for cell therapy and organoids - Stock Titan
Wed, 08 Jul 2026
Bio-Techne Launches Expanded R&D Systems AI-Engineered Designer Protein Portfolio - Sahm
Mon, 29 Jun 2026
Bio-Techne Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Bio-Techne Corporation - TECH - Business Wire
Fri, 26 Jun 2026
Bio-Techne Corporation (TECH) Merck KGaA - M&A Call - Slideshow (NASDAQ:TECH) 2026-06-26 - Seeking Alpha
Thu, 25 Jun 2026
Bio-Techne (TECH) Soars 20% on Merck $11.3B Merger - Yahoo Finance
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |